数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
This study aimed to investigate the association between the human telomerase reverse transcriptase gene (hTERT)-MNS16A polymorphism and cannabis or synthetic cannabinoid use disorder (CUD/SCUD).
方法
The study included a total of 228 participants, comprised of 147 CUD/SCUD patients and 81 healthy controls.；Analysis of the log-transformed T/S ratio indicated a significantly greater degree of LTL shortening in the patient group compared to the control group (p = 0.001).；Among patients, psychotic symptoms and violent behaviors were notably more prevalent in those with a T/S ratio > 1 compared to those with a T/S ratio < 1 (p = 0.022 and p = 0.011, respectively).
核心结论
Genotyping of the hTERT-MNS16A variant was performed through polymerase chain reaction (PCR), while relative LTL was measured using real-time PCR.；For analysis, the T/S ratio (telomere, T) was calculated in relation to a single-copy gene (S), allowing LTL to be expressed as the relative T/S ratio.；Analysis of the log-transformed T/S ratio indicated a significantly greater degree of LTL shortening in the patient group compared to the control group (p = 0.001). ‖ 结论：In summary, although the hTERT-MNS16A variable number tandem repeat polymorphism does not appear to increase susceptibility to CUD or SCUD, LTL shortening is evident in patients with these disorders.
局限
未能获取全文，具体设计细节、失访与统计学处理无法核验。
对本项目的价值
★★☆☆☆ 相关范围内，作为背景与横向对照收录。
原文题录
- 英文标题：Exploring the Role of Leukocyte Telomere Length and Human Telomerase Reverse Transcriptase MNS16A Variant in Cannabis or Synthetic Cannabinoid Use Disorder.
- 期刊与标识：Clin Psychopharmacol Neurosci · PMID 42947591 · DOI 10.9758/cpn.25.1389**
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。